Table 3.
Phase 3 trials evaluating novel agent-based continuous therapy for transplant-ineligible patients
→ indicates “followed by”; mPR, low-dose MPR; R, lenalidomide; and T, thalidomide.
Phase 3 trials evaluating novel agent-based continuous therapy for transplant-ineligible patients
→ indicates “followed by”; mPR, low-dose MPR; R, lenalidomide; and T, thalidomide.
